398 related articles for article (PubMed ID: 33268615)
1. [Short-term Glucose Lowering Effects of Sodium-glucose Cotransporter 2 Inhibitors Confirmed by Flash Glucose Monitoring in Two Outpatients with Type 1 Diabetes].
Habu M; Okada Y; Kurozumi A; Tanaka Y
J UOEH; 2020; 42(4):359-364. PubMed ID: 33268615
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Tofogliflozin on 24-h Glucose Profile Based on Continuous Glucose Monitoring: Crossover Study of Sodium-Glucose Cotransporter 2 Inhibitor.
Kurozumi A; Okada Y; Shimokawa M; Goshima Y; Otsuka T; Narisawa M; Torimoto K; Tanaka Y
Diabetes Technol Ther; 2019 Jul; 21(7):385-392. PubMed ID: 31210529
[No Abstract] [Full Text] [Related]
3. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.
Henry RR; Rosenstock J; Edelman S; Mudaliar S; Chalamandaris AG; Kasichayanula S; Bogle A; Iqbal N; List J; Griffen SC
Diabetes Care; 2015 Mar; 38(3):412-9. PubMed ID: 25271207
[TBL] [Abstract][Full Text] [Related]
4. Glucose-lowering effects of 7-day treatment with SGLT2 inhibitor confirmed by intermittently scanned continuous glucose monitoring in outpatients with type 1 diabetes. A pilot study.
Kurozumi A; Okada Y; Tanaka Y
Endocr J; 2021 Mar; 68(3):361-369. PubMed ID: 33208570
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Effects of SGLT2 Inhibitor Ipragliflozin and Metformin on NASH in Type 2 Diabetic Mice.
Tahara A; Takasu T
Endocr Res; 2020; 45(2):147-161. PubMed ID: 31955626
[No Abstract] [Full Text] [Related]
6. Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice.
Terasaki M; Hiromura M; Mori Y; Kohashi K; Nagashima M; Kushima H; Watanabe T; Hirano T
PLoS One; 2015; 10(11):e0143396. PubMed ID: 26606676
[TBL] [Abstract][Full Text] [Related]
7. Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients.
Mazidi M; Rezaie P; Gao HK; Kengne AP
J Am Heart Assoc; 2017 May; 6(6):. PubMed ID: 28546454
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of SGLT2 Inhibitors in Type 1 Diabetes After the Introduction of an Off-Label Use Protocol for Clinical Practice.
Bayona Cebada A; Nattero-Chávez L; Alonso Díaz S; Escobar-Morreale HF; Luque-Ramírez M
Diabetes Technol Ther; 2020 Mar; 22(3):208-215. PubMed ID: 31644310
[No Abstract] [Full Text] [Related]
9. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus.
Vallon V
Annu Rev Med; 2015; 66():255-70. PubMed ID: 25341005
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
Scheen AJ
Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
[TBL] [Abstract][Full Text] [Related]
11. Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes.
Sands AT; Zambrowicz BP; Rosenstock J; Lapuerta P; Bode BW; Garg SK; Buse JB; Banks P; Heptulla R; Rendell M; Cefalu WT; Strumph P
Diabetes Care; 2015 Jul; 38(7):1181-8. PubMed ID: 26049551
[TBL] [Abstract][Full Text] [Related]
12. Peripheral combination treatment of leptin and an SGLT2 inhibitor improved glucose metabolism in insulin-dependent diabetes mellitus mice.
Yaginuma H; Banno R; Sun R; Taki K; Mizoguchi A; Kobayashi T; Sugiyama M; Tsunekawa T; Onoue T; Takagi H; Hagiwara D; Ito Y; Iwama S; Suga H; Arima H
J Pharmacol Sci; 2021 Dec; 147(4):340-347. PubMed ID: 34663516
[TBL] [Abstract][Full Text] [Related]
13. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
Lingvay I
Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
[TBL] [Abstract][Full Text] [Related]
14. SGLT2 inhibitors provide an effective therapeutic option for diabetes complicated with insulin antibodies.
Hayashi A; Takano K; Kawai S; Shichiri M
Endocr J; 2016; 63(2):187-91. PubMed ID: 26549210
[TBL] [Abstract][Full Text] [Related]
15. SGLT-2 inhibitors as second-line therapy in type 2 diabetes.
Tahrani AA
Lancet Diabetes Endocrinol; 2014 Sep; 2(9):678-9. PubMed ID: 24948512
[No Abstract] [Full Text] [Related]
16. Clinical implication of SGLT2 inhibitors in type 2 diabetes.
Kim GW; Chung SH
Arch Pharm Res; 2014 Aug; 37(8):957-66. PubMed ID: 24950857
[TBL] [Abstract][Full Text] [Related]
17. The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study.
McGurnaghan SJ; Brierley L; Caparrotta TM; McKeigue PM; Blackbourn LAK; Wild SH; Leese GP; McCrimmon RJ; McKnight JA; Pearson ER; Petrie JR; Sattar N; Colhoun HM;
Diabetologia; 2019 Apr; 62(4):621-632. PubMed ID: 30631892
[TBL] [Abstract][Full Text] [Related]
18. [Euglycemic ketosis in an adolescent with type 1 diabetes on insulin and dapaglifozin: Case report].
Pereyra A M; Ramírez C; Román R
Rev Chil Pediatr; 2017 Jun; 88(3):404-410. PubMed ID: 28737202
[TBL] [Abstract][Full Text] [Related]
19. SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model.
Tahara A; Takasu T
Physiol Rep; 2019 Nov; 7(22):e14286. PubMed ID: 31782258
[TBL] [Abstract][Full Text] [Related]
20. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.
Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Li Q; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
Eur J Pharmacol; 2013 Sep; 715(1-3):246-55. PubMed ID: 23707905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]